Mylan Launches Generic Lipitor In Five European Countries
PITTSBURGH and LYON, France, May 11, 2012 /PRNewswire/ -- Mylan Inc. today announced that it has launched Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg in France, Belgium, the UK, the...
View ArticleCompletion Of 9.6MW Of PV Plants In Germany
ET Solar Group Corp. of China has announced completion of two ground-mounted PV power plants in Germany, with total installed capacity of over 9.6MW.The plants are ground-mounted and are 4MW and 5.6MW...
View ArticlePositive Phase 2 Study Results For Tivantinib In Previously Treated...
ArQule, Inc. and Daiichi Sankyo Co., Ltd. announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a...
View Article6-Year Follow-Up Data For Dasatinib Demonstrates 71 Percent Overall Survival...
Results Presented at the 17th Congress of the European Hematology Association by Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., said six-year follow-up results from a Phase 3...
View ArticleDNA Blood Test Detects Cancer Resistance
Two studies in Nature applied DNA blood testing using the BEAMing technology to detect drug resistance mediated by KRAS mutations in colorectal cancer patients months before treatment failure was...
View ArticleFood Allergies Double In The Last 10 Years
Life-threatening allergic reactions in children, such as anaphylaxis, have increased 7-fold in the last decade and a third of all allergic shocks in children occur for the first time at school with...
View ArticleDespite Available Treatments, Fewer Than 50% Of Asthmatic Children Control...
Hundreds of millions of people in the world suffer from allergies, and it is estimated that 300 million have asthma. In some countries, one in three children has asthma, and 80% of them also have other...
View ArticleHyperparathyroidism Treatments To Decline Due To Fewer Product Launches And...
GBI Research, a business intelligence provider, has released its latest research, 'Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product...
View ArticlePositive CHMP Opinion For Teduglutide For Patients With Short Bowel Syndrome
Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc. , jointly announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted...
View ArticleFerumoxytol Receives European Authorziation For Treatment Of Iron Deficiency...
Takeda Pharmaceutical Company Limited and AMAG Pharmaceuticals, Inc. today announced the granting of marketing authorization by the European Commission (EC) for ferumoxytol, a new intravenous (IV) iron...
View ArticlePositive Opinion For HUMIRA® In Non-radiographic Axial Spondyloarthritis From...
Abbott announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for HUMIRA (adalimumab) in adults with severe axial spondyloarthritis (axSpA) who...
View ArticleVELCADE Receives Positive EU Regulatory Recommendation For Subcutaneous...
Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending...
View ArticleShire's VPRIV® Shows Significant Improvement In Gaucher-Related Bone Disease
In a head-to-head trial between VPRIV and Cerezyme(R) (imiglucerase), only patients treated with VPRIV experienced statistically significant improvement in lumbar spine bone mineral density at 9...
View ArticleInterferon-Free Phase II Combination Trial With TMC435 And Daclatasvir
A phase II interferon-free combination study with TMC435 and daclatasvir will evaluate treatment-naive or previous null responder patients with HCV genotype 1a and 1b - The study will include approx....
View ArticlePositive EC Decision On Flutiform® Combination Therapy For Asthma
Mundipharma today announced the positive European Commission (EC) decision for flutiform(R) (fluticasone propionate/formoterol fumarate), a new combination therapy for the maintenance treatment of...
View ArticleEurartesim Anti-Malaria Drug Begins Roll Out
Eurartesim(R) - dihydroartemisinin piperaquine (DHA-PQP) - the first artemisinin combination therapy (ACT) has been approved by the European Medicines Agency (EMA) for the treatment of uncomplicated...
View Article